Drug Approval | July 17, 2025
SMS Lifesciences India receives EIR with VAI status from USFDA for API facility at Kazipally
The receipt of EIR reaffirms the company's commitment to maintaining global quality standards
The receipt of EIR reaffirms the company's commitment to maintaining global quality standards
The UK authorization is based on positive results from the Phase III OASIS-1, -2, and -3 trials
The company has been awarded a contract for the supply of essential pharmaceutical formulations to government health institutions across Rajasthan
Label updates reflect growing body of real-world evidence and regulatory confidence in the safety profile of the class of CD19- and BCMA-directed autologous CAR T cell therapies, reinforcing efforts to increase equitable access
Star Health Insurance is modernising its claims ecosystem to be future-ready
The inspection concluded with zero Form 483 observations
Operating income on consolidated basis increased by 38.10% at Rs 44.58 crore in Q4 FY25
Akums invested Rs. 272 crore in capital expenditure during FY25
Merck KGaA, Darmstadt, Germany announced the presentation of new oncology data across more than 12 tumor types at ASCO 2025
EBITDA before special items decreases to €4.08 billion (7.4%)
Subscribe To Our Newsletter & Stay Updated
